Onkure Therapeutics, INC. (OKUR) — 10-Q Filings

10-Q Filings (6)

• OnKure's Losses Widen Amid Increased R&D, Cash Dwindles to $70M — Nov 6, 2025 Risk: high
  OnKure Therapeutics, Inc. (OKUR) reported a net loss of $14.7 million for the three months ended September 30, 2025, an increase from a net loss of $11.6 millio
• OnKure's Losses Widen Amid Increased R&D Spend — Aug 12, 2025 Risk: high
  OnKure Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net loss
• OnKure Therapeutics Files Q1 2025 10-Q — May 6, 2025 Risk: medium
  OnKure Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Reneo Pharmaceuticals, Inc. until a name change on
• OnKure Therapeutics Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
  OnKure Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial position, including details on its equi
• Reneo Pharmaceuticals Files Q2 2024 10-Q — Aug 13, 2024 Risk: medium
  Reneo Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial condition and operations, including detail
• Reneo Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — May 7, 2024 Risk:
  Reneo Pharmaceuticals, Inc. (OKUR) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Reneo Pharmaceuticals, Inc. filed a 10-Q report for the period e

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX